Clinical Trial Update: Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating inflammatory and immunological changes in HIV-positive patients switching to DTG dual regimen versus B/F/TAF triple regimen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• B/F/TAF triple regimen (bictegravir/emtricitabine/tenofovir alafenamide)
• DTG dual regimen (dolutegravir-based dual regimen)

Snippet

Sponsor: Cristina Mussini | Conditions: HIV Infections | Phase 4 | Status: UNKNOWN